drugset / Trial / NCT02889822

The Tolerability of Alprostadil Liposome for Injection in Healthy Adult Volunteers

NCT02889822

Phase 1 Completed 44 enrolled Guangzhou Yipinhong Pharmaceutical CO.,LTD
NaSingle-groupOpen-labelTreatment

Summary

Conducted in Chinese healthy adult volunteers,the study aims to observe the safety and tolerability of single/multiple-dose administration of different doses of Alprostadil Liposome for Injection as well as to confirm the safety dose range.

Timeline

Start
2010-03
Primary completion
2010-12
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Alprostadil Unknown 10 ug Intravenous
Subject Alprostadil Unknown 20 ug Intravenous
Subject Alprostadil Unknown 50 ug Intravenous
Subject Alprostadil Unknown 100 ug Intravenous
Subject Alprostadil Unknown 200 ug Intravenous
Subject Alprostadil Unknown 300 ug Intravenous
Subject Alprostadil Unknown 400 ug Intravenous